ArticleFrontiers in pharmacology2026
Tuina ameliorates sleep disturbances in PCPA-treated rats through Piezo1-mediated calcium signaling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Insomnia is a prevalent sleep disorder that severely impairs physical and mental health. Clinical research has shown that Tuina, a form of therapeutic massage, can improve sleep quality and restore normal sleep patterns, yet the underlying biological mechanism remains unclear. This study aimed to determine whether Tuina improves sleep-related behaviors by modulating the Piezo1-calcium signaling pathway through mechanical stimulation of the nervous system. Materials and methods: A rat model of sleep disturbances was induced using PCPA. Rats received daily Tuina on the dorsal regions corresponding to the Governor Vessel and Bladder meridians. sleep-related behavioral parameters, cognitive function, hippocampal neurotransmitters, and expression of Piezo1 and downstream proteins (CaM, CaN) were assessed. The Piezo1 agonist Yoda1 was used to verify mechanistic involvement. Results: Tuina treatment significantly improved sleep-related behavioral parameters and cognitive performance in PCPA-treated rats. At the molecular level, PCPA-induced sleep disruption led to Piezo1 upregulation, intracellular calcium overload, and subsequent overactivation of the CaM/CaN signaling pathway. These alterations were accompanied by neurotransmitter imbalance and hippocampal neuronal damage. Tuina intervention effectively suppressed Piezo1 expression, normalized calcium homeostasis, and inhibited downstream CaM/CaN activation, thereby restoring neurotransmitter levels and preserving neuronal integrity. Critically, the therapeutic benefits of Tuina were largely reversed by co-administration of the Piezo1 agonist Yoda1, supporting the involvement of Piezo1-mediated calcium signaling in its mechanism of action. Conclusion: Tuina's therapeutic effect involves suppression of Piezo1-dependent calcium signaling, contributing to normalization of hippocampal function and neurotransmitter balance. This provides mechanistic evidence that Tuina's mechanical stimulation modulates sleep-related behavioral endpoints via central mechanosensitive ion channels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.